Safety and Efficacy of Percutaneous Arterial Port Implantation for Hepatic Arterial Infusion Chemotherapy

Overview

Journal Eur Radiol

Specialty Radiology

Date 2024 Jul 30

PMID 39080068

Authors

Louis Meyblum

Matthieu Faron

Frederic Deschamps

Adrian Kobe

Baptiste Bonnet

Alice Boileve

Maximilliano Gelli

Valerie Boige

Antoine Hollebecque

Jerome Durand-Labrunie

David Malka

Remy Barbe

Michel Ducreux

Thierry De Baere

Lambros Tselikas

Affiliations

Soon will be listed here.

Abstract

Objectives: Approximately 40% of patients with colorectal cancer will develop liver metastases. Hepatic arterial infusion chemotherapy (HAIC) represents a valuable treatment option, with curative, palliative, or adjuvant intent. The aim of our study was to describe technical considerations, safety, and oncological outcomes of patients receiving HAIC.

Materials And Methods: All patients who underwent percutaneous hepatic arterial port placement in our institution between 2004 and 2021 were included in this retrospective analysis. Demographic, anatomical and technical data were collected. Tumor response was assessed using RECIST 1.1. Kaplan-Meier estimates were used for overall survival (OS) and hepatic progression-free survival (PFS). Adverse events (AEs) were graded using the Clavien-Dindo classification.

Results: A total of 360 patients (median age, 58.6 years [interquartile range (IQR): 49.5-65.4]; 208 men [57.8%]) were included. Percutaneous hepatic arterial port placement was successful in 87.9% of cases, resulting in 379 port placements (431 attempts). Overall, 394 HAIC courses were delivered, mostly oxaliplatin-based (94.7%), with a median of 6 cycles per course (IQR: 3-8). AEs (all grades) were observed in 42.0% of ports (grade IIIb-V: 1.1%). Most port dysfunctions could be resolved, resulting in a 73.1% rate of HAIC resumption, without impact on OS. Median OS was 22 months (IQR: 18-24), and median hepatic PFS was 11 months (IQR: 9.5-13). Tumor downstaging allowed surgery in 35.6% of patients, with significantly longer median OS than non-operated patients (39 months [IQR: 33-79] versus 14 months [IQR: 12-16], p < 0.001).

Conclusion: This retrospective cohort study demonstrates the feasibility, safety, and efficacy of percutaneous hepatic arterial port placement with an impact on survival for selected patients.

Clinical Relevance Statement: Percutaneous hepatic arterial port placement is feasible, safe and effective with an impact on the survival of selected patients.

Key Points: Hepatic arterial infusion chemotherapy provides promising tumor response and overall survival, especially in cases of resection/ablation. Total complication rate of hepatic arterial infusion chemotherapy port use is high, but serious complications are rare. Port revision is often necessary but allows the resumption of hepatic arterial infusion chemotherapy without affecting overall survival.

References

McMillan D, McArdle C . Epidemiology of colorectal liver metastases. Surg Oncol. 2007; 16(1):3-5. DOI: 10.1016/j.suronc.2007.04.008. View

Simmonds P, Primrose J, Colquitt J, Garden O, Poston G, Rees M . Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006; 94(7):982-99. PMC: 2361241. DOI: 10.1038/sj.bjc.6603033. View

Breedis C, Young G . The blood supply of neoplasms in the liver. Am J Pathol. 1954; 30(5):969-77. PMC: 1942491. View

Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D . Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2007; 15(1):219-26. DOI: 10.1245/s10434-007-9581-7. View

Kemeny N, Melendez F, Capanu M, Paty P, Fong Y, Schwartz L . Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009; 27(21):3465-71. PMC: 3646304. DOI: 10.1200/JCO.2008.20.1301. View

Ye L, Liu T, Ren L, Wei Y, Zhu D, Zai S . Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013; 31(16):1931-8. DOI: 10.1200/JCO.2012.44.8308. View

Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S . Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2014; 26(4):702-708. DOI: 10.1093/annonc/mdu580. View

Levi F, Boige V, Hebbar M, Smith D, Lepere C, Focan C . Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2015; 27(2):267-74. DOI: 10.1093/annonc/mdv548. View

Goere D, Benhaim L, Bonnet S, Malka D, Faron M, Elias D . Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg. 2012; 257(1):114-20. DOI: 10.1097/SLA.0b013e31827b9005. View

10.

Boileve A, Maillard A, Wagner M, Dromain C, Laurent C, Dupont Bierre E . Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53.... BMC Cancer. 2020; 20(1):74. PMC: 6990591. DOI: 10.1186/s12885-020-6571-7. View

11.

Goere D, Pignon J, Gelli M, Elias D, Benhaim L, Deschamps F . Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). BMC Cancer. 2018; 18(1):787. PMC: 6080555. DOI: 10.1186/s12885-018-4697-7. View

12.

Buisman F, Homs M, Grunhagen D, Filipe W, Bennink R, Besselink M . Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. BMC Cancer. 2019; 19(1):327. PMC: 6451273. DOI: 10.1186/s12885-019-5515-6. View

13.

Biecker E, Roth F, Heller J, Schild H, Sauerbruch T, Schepke M . Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2007; 19(10):846-52. DOI: 10.1097/MEG.0b013e3282eeb488. View

14.

Thiels C, DAngelica M . Hepatic artery infusion pumps. J Surg Oncol. 2020; 122(1):70-77. PMC: 9014308. DOI: 10.1002/jso.25913. View

15.

Furuta M, Watanabe J, Aramaki T, Notsu A, Yasui H . Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies. In Vivo. 2019; 34(1):275-282. PMC: 6984114. DOI: 10.21873/invivo.11771. View

16.

Li Q, He M, Chen H, Fang W, Zhou Y, Xu L . Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2021; 40(2):150-160. DOI: 10.1200/JCO.21.00608. View

17.

Lyu N, Wang X, Li J, Lai J, Chen Q, Li S . Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2021; 40(5):468-480. DOI: 10.1200/JCO.21.01963. View

18.

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

19.

Buisman F, Filipe W, Galjart B, Grunhagen D, Homs M, Moelker A . Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis. HPB (Oxford). 2021; 24(3):299-308. DOI: 10.1016/j.hpb.2021.10.014. View

20.

Kemeny N, Gonen M . Hepatic arterial infusion after liver resection. N Engl J Med. 2005; 352(7):734-5. DOI: 10.1056/NEJM200502173520723. View